Abstract
Interleukin-6 (IL-6) has been linked to a myriad of diseases associated with inflammation, including rheumatoid arthritis (RA), Crohns disease, and several types of cancer. In 2009 the US Food and Drug Administration accepted a complete-response submission for the use of Actemra (tocilizumab), the first humanized IL-6 receptor-inhibiting monoclonal antibody, for the treatment of RA. Although this treatment will certainly help in managing inflammatory disorders such as RA, we suggest that side effects of such blockade may be excess weight gain and hyperlipidemia.
Original language | English |
---|---|
Pages (from-to) | 396-398 |
Number of pages | 3 |
Journal | Clinical Pharmacology & Therapeutics |
Volume | 87 |
Issue number | 4 |
DOIs |
|
Publication status | Published - Apr 2010 |
Externally published | Yes |